This page shows the latest Hypertrophic cardiomyopathy news and features for those working in and with pharma, biotech and healthcare.
SMA), myasthenia gravis and hypertrophic cardiomyopathy.
Bristol Myers Squibb has reported some new analysis for its investigational cardiovascular drug mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). ... Hypertrophic cardiomyopathy (HCM) is a chronic and progressive disease which
The US Food and Drug Administration (FDA) is set to review Bristol Myers Squibb’s (BMS) investigational candidate mavacamten for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). ... Hypertrophic cardiomyopathy (HCM) is a
As part of the merger, BMS has now gained the rights to MyoKardia’s investigational treatment mavacamten, which is currently in development for obstructive hypertrophic cardiomyopathy (HCM).
In the process, BMS will gain the rights to MyoKardia’s investigational treatment mavacamten, which is currently being developed as a treatment for obstructive hypertrophic cardiomyopathy (HCM), wherein the wall between
Sanofi has licensing rights to three of MyoKardia's programmes in the two most common inherited cardiomyopathies, including two projects looking at hypertrophic cardiomyopathy (HCM) and one focusing on dilated cardiomyopathy ... MyoKardia's approach
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
For a registry study, Novartis asked patients to complete the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which tracks physical limitations, symptom frequency, social limitation and quality of life. ... MyoKardia is gathering PROs in its
Myokardia will develop two HCM (hypertrophic cardiomyopathy) programmes where it retains US commercialisation rights and Sanofi has ex-US rights; and a third DCM (dilated cardiomyopathy) programme will be developed by
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...